Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Taurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurine SCHEMBL28279946 | 1.00 | — | — | |
| Taurine SCHEMBL42632 | 0.97 | BLM (1.00) | — | |
| Taurine SCHEMBL30179154 | 0.97 | — | — | |
| Taurine SCHEMBL30191395 | 0.97 | — | — | |
| Taurine SCHEMBL23068 | 0.97 | — | — | |
| Taurine SCHEMBL10952596 | 0.93 | — | — | |
| Taurine SCHEMBL11449240 | 0.93 | — | — | |
| Taurine SCHEMBL8052521 | 0.93 | BLM (0.93) | — | |
| Taurine SCHEMBL19438470 | 0.93 | — | — | |
| Taurine SCHEMBL466027 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930479-A | Preparation method of taurinamide hydrochloride | 安徽昊帆生物有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-117642047-A | Preparation method of large-area lead-tin perovskite film for large-scale mass production | 南京大学 | 2024-03-01 | — | — | CN | claimed |
| CN-114539106-B | Synthetic method of stable isotope labeled taurinamide hydrochloride | 梯尔希（南京）药物研发有限公司 | 2023-05-02 | — | — | CN | claimed |
| US-20230056314-A1 | CYTOPROTECTIVE COMPOSITIONS FOR SHORT-TERM CELLS STORAGE AND TRANSPORTATION WITHOUT CRYOPRESERVATION AND DEEP FREEZING | Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956 (IN) | 2023-02-23 | — | — | US | claimed |
| CN-114539106-A | Synthetic method of stable isotope labeled tauryl amine hydrochloride | 梯尔希（南京）药物研发有限公司 | 2022-05-27 | — | — | CN | claimed |
| US-11015152-B2 | Cleansing bars with taurine | COLGATE-PALMOLIVE COMPANY (US) | 2021-05-25 | — | — | US | claimed |
| CN-111728180-A | Chicken-flavored seasoning without animal ingredients | 湖北飘扬食品科技有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-108713054-B | Cleansing bar containing taurine | 高露洁-棕榄公司 | 2020-09-29 | — | — | CN | claimed |
| EP-3383984-B1 | CLEANSING BARS WITH TAURINE | COLGATE PALMOLIVE CO (US) | 2020-03-11 | — | — | EP | claimed |
| EP-3220879-B1 | CLEANSING BARS WITH TAURINE | COLGATE PALMOLIVE CO (US) | 2020-03-04 | — | — | EP | claimed |
| EP-1882476-B1 | Preparation of antimicrobial formulation comprising 7-oxo-2-thia-1,5-diazabicyclo[3.3.1]-nonan-2,2-dion | HERDEIS CLAUS (DE) | 2008-11-19 | — | — | EP | claimed |
| EP-1882476-A1 | Preparation of antimicrobial formulation comprising 7-oxo-2-thia-1,5-diazabicyclo[3.3.1]-nonan-2,2-dion | HERDEIS, Claus (DE) | 2008-01-30 | — | — | EP | claimed |
| US-7034012-B2 | Composition and method for prevention and treatment of arrhythmias | RATH MATTHIAS | 2006-04-25 | — | — | US | claimed |
| EP-1330428-B1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE | SIGMA TAU IND FARMACEUTI (IT) | 2005-12-14 | — | — | EP | claimed |
| US-20050009904-A1 | Composition and method for prevention and treatment of arrhythmias | RATH MATTHIAS (US) | 2005-01-13 | — | — | US | claimed |
| US-20040024061-A1 | Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride | ALFASIGMA S.P.A. (IT) | 2004-02-05 | — | — | US | claimed |
| EP-1330428-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-07-30 | — | — | EP | claimed |
| WO-2002036543-A1 | SOLID COMPOSITIONS SUITABLE FOR ORAL ADMINISTRATION CONTAINING NON-HYGROSCOPIC SALTS OF L-CARNITINE AND THE ALKANOYL L-CARNITINES WITH TAURINE CHLORIDE AND GLYCINE CHLORIDE | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-05-10 | — | — | WO | claimed |
| EP-0863133-B1 | Process for the preparation of 2-amino-ethanesulfonylazide acid additon salts, 2-amino-ethanesulfonylazide hydrochloride as well as its use | HERDEIS CLAUS (DE) | 2001-09-26 | — | — | EP | claimed |
| EP-0863133-A2 | Process for the preparation of 2-amino-ethanesulfonylazide acid addition slats, 2-amino-ethanesulfonylazide hydrochloride as well as its use | HERDEIS, Claus (DE) | 1998-09-09 | — | — | EP | claimed |